$Novo Nordisk AS(NVO.US) If you saw this message and bought on the 23rd, it has now rebounded to around 60. The power of NVO's weight-loss drug should be more optimistic in the long term. Those with heavy positions can reduce a bit. Next week, focus on credit card and bank-related stocks, Visa, Master card, Capital One.
Trump proposed to set the U.S. credit card interest rate cap at 10% starting from January 20, 2026, for one year.
$Novo Nordisk AS(NVO.US)
On Monday, Wegovy oral weight-loss drug was approved by the FDA and is expected to be launched in the U.S. in January next year. The product is an oral tablet suitable for people aged 12 and above, providing a new option for users who are afraid of injections, which is expected to expand the potential user base. With a first-mover advantage in the time window, this will help Novo Nordisk capture the weight-loss drug market share and secure a more favorable position in future competition.
From the perspective of stock performance, the short-term target is around 60; in the medium to long term, as the oral weight-loss drug gradually gains traction and the market space continues to expand, the stock price may challenge and even break previous highs.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
